Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nimorazole→

Nimorazole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
6506-37-2
Molecular formula
C9H14N4O3
Molecular weight
226.23 g/mol
Drug class
5-nitroimidazolehypoxic-cell radiosensitiser and antiprotozoal agent
Mechanism of action
Under low-oxygen conditions, nitroimidazole reduction produces reactive intermediates that mimic oxygen fixation of radiation-induced DNA damage, increasing radiosensitivity of hypoxic tumour cells. It also produces DNA damage in susceptible protozoa and anaerobic organisms.
Indications / reported uses
  • Used as a radiosensitiser with radiotherapy for selected head-and-neck squamous-cell carcinomas in countries where authorised
  • Antiprotozoal and anaerobic antibacterial uses are country- and product-specific and should not be inferred from the radiosensitiser indication

Sources: PubMed — Nimorazole hypoxic-cell radiosensitiser clinical studies · NLM MeSH — Nimorazole · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nimorazole Environmental Risk Assessment (ERA) (the Nimorazole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.